Patient data collective and research matching AI
Hyper-Care
Hyper-Care is a patient data collective and community-driven health intelligence platform for rare, chronic, oncology, and underserved conditions. Public materials say patients can link health records, devices, claims, surveys, and genomic data; use AI tools to understand records and navigate care; join community registries; match with studies; and receive compensation when their data or participation supports research and development. The model could expand agency if consent, pod/key custody, revocation, compensation, sponsor visibility, and AI boundaries work as described, but public evidence did not include full privacy/terms, certification proof, independent audit, deployed-customer evidence, or validation of the advertised recruitment and real-world-evidence claims.
Public-source research has been drafted; final human publication review and change-log detail are still required.
Summary judgment · 78% toward patient-directed
Potentially agency-expanding, with commercialization and disclosure caveats
Hyper-Care is framed around patient data ownership, consent, value sharing, AI care navigation, and community-led research infrastructure. The axis position is lower than a fully verified patient-controlled system because life-sciences marketplace interests are central and key governance claims remain unverified.
Patient agency
How this tool changes agency
Patient-facing claims include record organization, plain-language result explanations, trend spotting, appointment preparation, care-team sharing, community support, and study matching.
Public pages claim granular consent, explicit opt-in permission, visible partners, revocation-style permissions, and compensation. Actual consent screens, privacy terms, revocation, sponsor contracts, and account deletion were not verified.
Patient-facing signals
Who does this AI serve?
Patient ownership and control are central public claims, but the platform also explicitly serves advocacy groups, researchers, CROs, life sciences sponsors, payers, and providers.
Can patients tell AI is involved?
Public pages describe safe AI, personalized AI tools, AI-powered care navigation, smart study matching, AI advocate features, and public demo AI assistant prompts.
Can patients meaningfully choose?
Public pages claim granular consent, explicit opt-in permission, visible partners, revocation-style permissions, and compensation. Actual consent screens, privacy terms, revocation, sponsor contracts, and account deletion were not verified.
Can patients correct or challenge what the AI produces?
Demo strings suggest permission grants, records, AI history, and local saved conversations, but public materials do not clearly describe transcript/data correction, AI-answer challenge, study-match appeal, or sponsor-data dispute workflows.
Does it help patients understand or act?
Patient-facing claims include record organization, plain-language result explanations, trend spotting, appointment preparation, care-team sharing, community support, and study matching.
Text findings
Who is left out or burdened?
Digital, identity, privacy-literacy, language, and trial-access burdens remain unclear
Hyper-Care targets rare/chronic/underserved communities, but public materials assume EHR/device connectivity, identity verification, English-language use, digital access, data-sharing literacy, and comfort with compensation/trial decisions. Accessibility, multilingual support, caregiver/proxy safeguards, and low-literacy workflows were not documented.
What happens to patient data?
Strong control claims, incomplete public governance
Hyper-Care claims patient-held keys, Solid-style pods, opt-in sharing, no scraping, aggregated insight monetization, AES-256 encryption, zero-knowledge cryptography, FHIR integration, HIPAA/GDPR/SOC2/HITRUST alignment, visible sponsors, and compensation. Public evidence did not include a full privacy policy, terms, BAA, certification proof, subprocessor list, retention/deletion policy, model-training policy, de-identification method, or revenue-sharing formula.
Are the clinical boundaries clear?
Partial / unclear
Public/demo claims include lab explanation, medication interaction questions, symptom analysis, wellness suggestions, study matching, and urgent safety guidance. Public materials did not clearly define medical-advice limits, clinician review, FDA/regulatory posture, emergency escalation, or responsibility for incorrect AI guidance.
Who defined what good looks like?
Vendor/community/sponsor-defined, independent evidence missing
The stated model centers patients and advocacy groups, but public evidence did not show patient governance bylaws, community voting rights, independent outcome evaluation, IRB/research governance examples, or external privacy/security validation.
Review method
Deep public-source review of the Hyper-Care homepage, Patients, Advocacy, Life Sciences, Trust, Values, FAQ, Careers, public feed metadata, and public demo web app/source-map strings; no account creation, real health-data connection, patient interview, sponsor interview, security audit, certification audit, privacy/legal review, clinical review, or independent outcome validation.
Draft profile · Low-to-medium draft, official sources and public demo inspection only